We are an emerging leader with new solutions in the field of nuclear medicine technology

– Accelerator technology key component of NorthStar’s multi-pronged Mo-99 production strategy – BELOIT, Wis.

– Positive RadioGenix System market momentum continues – – Increasing weekly domestic production of non-uranium based Mo-99 – Highlights include: Strategically-planned RadioGenix System roll out on track; initial units in use Numerous RadioGenix System commercial sites in regulatory licensure review process; many additional sites anticipated in 2019 Every week, an increasing number of technetium-99m (Tc-99m) patient doses are dispensed using RadioGenix Systems and non-uranium molybdenum-99 (Mo-99) NorthStar recognized by U.S.

BELOIT, Wis. – December 18, 2018 –NorthStar Medical Technologies, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced the appointment of Paul Estrem, CPA, as Senior Vice President and Chief Financial Officer.